



**Santen Presents at a Global Cell Therapy Conference
- The Cell & Gene Meeting on the Mediterranean**

April 6, 2021, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) announced today that Santen would make a presentation at a global cell therapy conference: the Cell & Gene Meeting on the Mediterranean held from April 6 to 9.

Cell therapy is a rapidly evolving therapeutic area, with the potential to completely transform the lives of people living with previously incurable diseases. As a new player in this exciting and revolutionary field, Santen's Cell Therapy team is looking to collaborate with key stakeholders in order to shape relevant policies, forge meaningful partnerships and create an optimal environment for the launch of jCell.

As an important first step in achieving this goal Santen recently joined the [Alliance for Regenerative Medicine](#) (hereinafter, ARM), a leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. As the global voice of the sector, ARM represents the interests of 360+ members across 25 countries, including small and large companies, academic research institutions, major medical centers and patient groups. Since joining, Santen Cell Therapy members have been collectively tackling some of the most pressing challenges in the regenerative medicine sector through regular participation in ARM's specialized committees.

Shortly after joining, we received the news that we had been selected to present at ARM's annual event, the [Cell & Gene Meeting on the Mediterranean](#), along with a number of other leading companies in the regenerative medicine field. Held virtually on April 6 to 9, this is a high-level event featuring more than 80 dedicated company presentations by C-level executives, highlighting technical and clinical achievements over the past 12 months. The meeting also includes over 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization. CEO Shigeo Taniuchi presented on behalf of Santen, through a pre-recorded presentation that will air on the virtual conference platform.

A few weeks earlier, Head of Cell Therapy Gil Carrasquinho was invited to present at the [8th Annual Biologics Manufacturing Asia](#), a conference that also brought together numerous biopharmaceutical industry stakeholders, this time around the topic of cell therapy manufacturing. Held on March 17, this was an opportunity to share technical expertise and learn about the latest best practices in the cell therapy community. We presented our experience, goals and ideas for advanced medicines in the ophthalmology field.

We are grateful to have the opportunity to highlight our vision and goals in the cell therapy field and to be a part of the important and insightful conversations taking place in this rapidly advancing environment. We hope that these events will be the first of many opportunities to engage with leading players in this exciting field.

Contact

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com